Cassava Sciences, Inc. Gains 35.65%

Cassava Sciences, Inc. (SAVA:NASDAQ) shot up at $51.06, a gain of 35.7%. On Thu, Sep 22, 2022, SAVA:NASDAQ hit a New 2-Week High of $51.06. The stock got featured on our News Catalysts scanner on Thu, Sep 08, 2022 at 10:31 AM in the 'MISCELLANEOUS' category. From Thu, Sep 08, 2022, the stock recorded 50.00% Up Days and 54.55% Green Days

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.